Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B (PUPs B-LONG)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02234310
Recruitment Status : Completed
First Posted : September 9, 2014
Results First Posted : July 31, 2020
Last Update Posted : July 31, 2020
Sponsor:
Collaborator:
Swedish Orphan Biovitrum
Information provided by (Responsible Party):
Sanofi ( Bioverativ, a Sanofi company )

Study Type Interventional
Study Design Allocation: N/A;   Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition Hemophilia B
Intervention Biological: rFIXFc
Enrollment 33
Recruitment Details The study was conducted at 28 active centers in 11 countries. Participants were screened between 13-Nov-2014 to 23-Jul-2018.
Pre-assignment Details A total of 38 participants were screened. A total of 33 participants were enrolled, 22 participants began study participation on episodic treatment regimen and 11 participants began study participation on prophylactic treatment regimen.
Arm/Group Title Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc)
Hide Arm/Group Description Participants received rFIXFc intravenous (IV) injection as follows: Prophylactic treatment regimen: started with rFIXFc 50 International Units per kilogram (IU/kg) weekly until a participant reached at least 50 exposure days (ED=24-hour period in which greater than or equal to (>=1) injection/dose of rFIXFc was given) to rFIXFc, withdrawal from study or end of study. Adjustments to dose and dosing interval was based on incremental recovery, subsequent Factor IX levels, physical activity, bleeding pattern, in accordance with local standards of care for prophylactic regimen (PR). Treatment with episodic (on demand) regimen can be initiated before PR at investigators discretion. Episodic (On demand; optional): rFIXFc at individual doses based on participant's clinical condition, type and severity of bleeding event until PR.
Period Title: Overall Study
Started 33
Episodic Treatment Regimen 22 [1]
Prophylactic Treatment Regimen 28 [2]
Completed 27
Not Completed 6
Reason Not Completed
Physician Decision             1
Adverse Event             1
Eligibility Criteria not fulfilled             2
Withdrawal by Subject             2
[1]
Participants were treated in more than one regimen and counted in all categories wherever applicable
[2]
17 participants among the 22 who started in episodic regimen, switched to the prophylactic regimen.
Arm/Group Title Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc)
Hide Arm/Group Description Participants received rFIXFc IV injection as follows: Prophylactic treatment regimen: started with rFIXFc 50 IU/kg weekly until a participant reached at least 50 exposure days (ED=24-hour period in which >=1 injection/dose of rFIXFc was given) to rFIXFc, withdrawal from study or end of study. Adjustments to dose and dosing interval was based on incremental recovery, subsequent Factor IX levels, physical activity, bleeding pattern, in accordance with local standards of care for prophylactic regimen (PR). Treatment with episodic (on demand) regimen can be initiated before PR at investigators discretion. Episodic (On demand; optional): rFIXFc at individual doses based on participant's clinical condition, type and severity of bleeding event until PR.
Overall Number of Baseline Participants 33
Hide Baseline Analysis Population Description
Analysis was performed on Safety Analysis Set which included all participants who received at least 1 dose of study rFIXFc.
Age, Continuous  
Median (Full Range)
Unit of measure:  Years
Number Analyzed 33 participants
0.60
(0.08 to 2.00)
Sex: Female, Male  
Measure Type: Count of Participants
Unit of measure:  Participants
Number Analyzed 33 participants
Female
0
   0.0%
Male
33
 100.0%
Race/Ethnicity, Customized  
Measure Type: Count of Participants
Unit of measure:  Participants
Number Analyzed 33 participants
White
22
  66.7%
Black or African-American
1
   3.0%
Asian
1
   3.0%
American Indian or Alaska Native
0
   0.0%
Native Hawaiian or other Pacific Islander
0
   0.0%
Unknown or Not reported
5
  15.2%
Other
4
  12.1%
1.Primary Outcome
Title Percentage of Participants With Confirmed Inhibitor Development as Measured by the Nijmegen-Modified Bethesda Assay
Hide Description Development of an inhibitor was defined as an inhibitor test result of >= 0.60 Bethesda units per milliliter (BU/mL) that was confirmed by a second test result of >=0.60 BU/mL from a separate sample, drawn 2 to 4 weeks after the date when the original sample was drawn, with both tests performed by the central laboratory using Nijmegen-modified Bethesda assay.
Time Frame Up to 3 years
Hide Outcome Measure Data
Hide Analysis Population Description
Analysis performed on Safety Analysis set which included all participants who had received at least 1 dose of study treatment.
Arm/Group Title Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc)
Hide Arm/Group Description:
Participants received rFIXFc IV injection as follows: Prophylactic treatment regimen: started with rFIXFc 50 IU/kg weekly until a participant reached at least 50 exposure days (ED=24-hour period in which >=1 injection/dose of rFIXFc was given) to rFIXFc, withdrawal from study or end of study. Adjustments to dose and dosing interval was based on incremental recovery, subsequent Factor IX levels, physical activity, bleeding pattern, in accordance with local standards of care for prophylactic regimen (PR). Treatment with episodic (on demand) regimen can be initiated before PR at investigators discretion. Episodic (On demand; optional): rFIXFc at individual doses based on participant's clinical condition, type and severity of bleeding event until PR.
Overall Number of Participants Analyzed 33
Measure Type: Number
Number (95% Confidence Interval)
Unit of Measure: percentage of participants
3.03
(0.08 to 15.76)
2.Secondary Outcome
Title Annualized Number of Bleeding Episodes (Spontaneous and Traumatic) Per Participant (Annualized Bleeding Rate [ABR])
Hide Description ABR was annualized number of bleeding episodes during efficacy period (EP) per participant normalized to a 1-year interval of time. Bleeding episodes were classified as: spontaneous if parent/caregiver/participant records bleeding event when there is no known contributing factor such as definite trauma or antecedent strenuous activity; and traumatic when there is known reason for bleed. ABR=(Number of bleeding episodes during EP/total number of days during EP)*365.25. EP reflects the sum of all intervals of time during which participants were treated with rFIXFc per treatment regimens excluding surgical/rehabilitation periods and large injection intervals (greater than [>]28 days). Participants were included in summary of more than 1 treatment regimen if their regimen changed during study.
Time Frame Up to 3 years
Hide Outcome Measure Data
Hide Analysis Population Description
Analysis performed on Full Analysis Set (FAS) which included all enrolled participants with at least 1 dose of study treatment. Here, number analyzed signifies number of FAS participants who were analyzed in each treatment regimen.
Arm/Group Title Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc)
Hide Arm/Group Description:
Participants received rFIXFc IV injection as follows: Prophylactic treatment regimen: started with rFIXFc 50 IU/kg weekly until a participant reached at least 50 exposure days (ED=24-hour period in which >=1 injection/dose of rFIXFc was given) to rFIXFc, withdrawal from study or end of study. Adjustments to dose and dosing interval was based on incremental recovery, subsequent Factor IX levels, physical activity, bleeding pattern, in accordance with local standards of care for prophylactic regimen (PR). Treatment with episodic (on demand) regimen can be initiated before PR at investigators discretion. Episodic (On demand; optional): rFIXFc at individual doses based on participant's clinical condition, type and severity of bleeding event until PR.
Overall Number of Participants Analyzed 33
Median (Full Range)
Unit of Measure: episodes per participant per year
Episodic regimen Number Analyzed 22 participants
0.21
(0.0 to 6.8)
Prophylaxis regimen Number Analyzed 28 participants
1.24
(0.0 to 5.4)
3.Secondary Outcome
Title Annualized Number of Spontaneous Joint Bleeding Episodes
Hide Description Bleeding episodes were classified as spontaneous if parent/caregiver/participant records a bleeding event when there is no known contributing factor such as a definite trauma or antecedent "strenuous" activity. Annualized spontaneous joint bleeding episodes=(Total number of spontaneous joint bleeding episodes during efficacy period (EP) divided by total number of days during EP)*365.25. EP reflects the sum of all intervals of time during which participants were treated with rFIXFc per treatment regimen excluding major and minor surgical/rehabilitation periods and large injection intervals (>28 days). Participants were included in summary of more than 1 treatment regimen if their regimen changed during study.
Time Frame Up to 3 years
Hide Outcome Measure Data
Hide Analysis Population Description
Analysis performed on FAS. Here, number analyzed signifies number of FAS participants who were analyzed in each treatment regimen.
Arm/Group Title Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc)
Hide Arm/Group Description:
Participants received rFIXFc IV injection as follows: Prophylactic treatment regimen: started with rFIXFc 50 IU/kg weekly until a participant reached at least 50 exposure days (ED=24-hour period in which >=1 injection/dose of rFIXFc was given) to rFIXFc, withdrawal from study or end of study. Adjustments to dose and dosing interval was based on incremental recovery, subsequent Factor IX levels, physical activity, bleeding pattern, in accordance with local standards of care for prophylactic regimen (PR). Treatment with episodic (on demand) regimen can be initiated before PR at investigators discretion. Episodic (On demand; optional): rFIXFc at individual doses based on participant's clinical condition, type and severity of bleeding event until PR.
Overall Number of Participants Analyzed 33
Median (Full Range)
Unit of Measure: episodes per participant per year
Episodic regimen Number Analyzed 22 participants
0.00
(0.0 to 5.6)
Prophylaxis regimen Number Analyzed 28 participants
0.00
(0.0 to 2.6)
4.Secondary Outcome
Title Number of rFIXFc Injections With Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
Hide Description Using e-diary, each participant's parent/caregiver rated treatment response to any bleeding episode (BE) at approximately 8 to 12 hours from time of injection and prior to additional doses of rFIXFc given for same BE using 4-point scale:- 1=Excellent: abrupt pain relief and/or improvement in signs of bleeding within approximately 8 hours after initial injection; 2=Good: definite pain relief and/or improvement in signs of bleeding within approx. 8 hours after injection, but possibly requiring more than 1 injection after 24-48 hours for complete resolution; 3=Moderate: Probable/slight beneficial effect within 8 hours after initial injection and requires more than 1 injection and 4=None: No improvement or condition worsens within approx. 8 hours after initial injection. Participants were included in summary of more than 1 treatment regimen if their regimen changed during study.
Time Frame Up to 3 years
Hide Outcome Measure Data
Hide Analysis Population Description
Analysis performed on FAS. Analysis was based on all injections. Here, number analyzed signifies number of responses to injections reported for each treatment regimen.
Arm/Group Title Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc)
Hide Arm/Group Description:
Participants received rFIXFc IV injection as follows: Prophylactic treatment regimen: started with rFIXFc 50 IU/kg weekly until a participant reached at least 50 exposure days (ED=24-hour period in which >=1 injection/dose of rFIXFc was given) to rFIXFc, withdrawal from study or end of study. Adjustments to dose and dosing interval was based on incremental recovery, subsequent Factor IX levels, physical activity, bleeding pattern, in accordance with local standards of care for prophylactic regimen (PR). Treatment with episodic (on demand) regimen can be initiated before PR at investigators discretion. Episodic (On demand; optional): rFIXFc at individual doses based on participant's clinical condition, type and severity of bleeding event until PR.
Overall Number of Participants Analyzed 33
Overall Number of Units Analyzed
Type of Units Analyzed: Responses to injections
154
Count of Units
Unit of Measure: responses to injections
Episodic regimen Number Analyzed 80 responses to injections
Excellent or Good
22
  27.5%
Moderate
0
   0.0%
None
0
   0.0%
Response not provided
58
  72.5%
Prophylaxis regimen Number Analyzed 74 responses to injections
Excellent or Good
50
  67.6%
Moderate
6
   8.1%
None
1
   1.4%
Response not provided
17
  23.0%
5.Secondary Outcome
Title Total Number of Exposure Days (EDs)
Hide Description An ED was defined as a 24-hour period in which a participant received one or more doses of rFIXFc injections, with the time of the first injection of rFIXFc defined as the start of the ED. Participant who did not have a particular injection type were counted as having zero injections for that type.
Time Frame Up to 3 years
Hide Outcome Measure Data
Hide Analysis Population Description
Analysis performed on safety analysis set.
Arm/Group Title Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc)
Hide Arm/Group Description:
Participants received rFIXFc IV injection as follows: Prophylactic treatment regimen: started with rFIXFc 50 IU/kg weekly until a participant reached at least 50 exposure days (ED=24-hour period in which >=1 injection/dose of rFIXFc was given) to rFIXFc, withdrawal from study or end of study. Adjustments to dose and dosing interval was based on incremental recovery, subsequent Factor IX levels, physical activity, bleeding pattern, in accordance with local standards of care for prophylactic regimen (PR). Treatment with episodic (on demand) regimen can be initiated before PR at investigators discretion. Episodic (On demand; optional): rFIXFc at individual doses based on participant's clinical condition, type and severity of bleeding event until PR.
Overall Number of Participants Analyzed 33
Median (Full Range)
Unit of Measure: days
76.0
(1 to 137)
6.Secondary Outcome
Title Total Annualized rFIXFc Consumption Per Participant for the Prevention and Treatment of Bleeding Episodes
Hide Description Total annualized rFIXFc consumption (in IU/kg) was calculated for each participant as: Annualized consumption = (Total IU/kg of rFIXFc during efficacy period (EP) divided by total number of days during EP)*365.25. EP reflects the sum of all intervals of time during which participants were treated with rFIXFc according to the treatment regimens of the study excluding surgical/rehabilitation periods and large injection intervals (> 28 days). Participants were included in summary of more than 1 treatment regimen if their regimen changed during study.
Time Frame Up to 3 years
Hide Outcome Measure Data
Hide Analysis Population Description
Analysis performed on FAS. Here, number analyzed signifies number of FAS participants who were analyzed in each treatment regimen.
Arm/Group Title Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc)
Hide Arm/Group Description:
Participants received rFIXFc IV injection as follows: Prophylactic treatment regimen: started with rFIXFc 50 IU/kg weekly until a participant reached at least 50 exposure days (ED=24-hour period in which >=1 injection/dose of rFIXFc was given) to rFIXFc, withdrawal from study or end of study. Adjustments to dose and dosing interval was based on incremental recovery, subsequent Factor IX levels, physical activity, bleeding pattern, in accordance with local standards of care for prophylactic regimen (PR). Treatment with episodic (on demand) regimen can be initiated before PR at investigators discretion. Episodic (On demand; optional): rFIXFc at individual doses based on participant's clinical condition, type and severity of bleeding event until PR.
Overall Number of Participants Analyzed 33
Median (Full Range)
Unit of Measure: IU per kilogram per participant per year
Episodic regimen Number Analyzed 22 participants
203.2
(0 to 5719)
Prophylaxis regimen Number Analyzed 28 participants
3175.0
(2544 to 13164)
7.Secondary Outcome
Title Number of Injections of rFIXFc Required to Resolve a Bleeding Episode
Hide Description Number of injections of rFIXFc required to resolve a bleeding episode during efficacy period (EP) were reported. EP reflects the sum of all intervals of time during which participants were treated with rFIXFc according to the treatment regimens of the study excluding surgical/rehabilitation periods and large injection intervals (>28 days). All injections given from the initial sign of a bleed, until the last date/time within the bleed window were counted. Participants were included in summary of more than 1 treatment regimen if their regimen changed during study.
Time Frame Up to 3 years
Hide Outcome Measure Data
Hide Analysis Population Description
Analysis performed on FAS. Here, number analyzed signifies number of bleeding episodes reported for each treatment regimen.
Arm/Group Title Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc)
Hide Arm/Group Description:
Participants received rFIXFc IV injection as follows: Prophylactic treatment regimen: started with rFIXFc 50 IU/kg weekly until a participant reached at least 50 exposure days (ED=24-hour period in which >=1 injection/dose of rFIXFc was given) to rFIXFc, withdrawal from study or end of study. Adjustments to dose and dosing interval was based on incremental recovery, subsequent Factor IX levels, physical activity, bleeding pattern, in accordance with local standards of care for prophylactic regimen (PR). Treatment with episodic (on demand) regimen can be initiated before PR at investigators discretion. Episodic (On demand; optional): rFIXFc at individual doses based on participant's clinical condition, type and severity of bleeding event until PR.
Overall Number of Participants Analyzed 33
Overall Number of Units Analyzed
Type of Units Analyzed: Bleeding episodes
85
Median (Full Range)
Unit of Measure: injections
Episodic regimen Number Analyzed 27 Bleeding episodes [1] 
1.0
(1 to 31)
Prophylaxis regimen Number Analyzed 58 Bleeding episodes [2] 
1.0
(1 to 4)
[1]
22 participants
[2]
28 participants
8.Secondary Outcome
Title Average Dose Per Injection of rFIXFc Required to Resolve a Bleeding Episode
Hide Description The average dose of rFIXFc per injection per bleeding episode was calculated as the average of all doses (IU/kg) administered to treat the bleeding episode during efficacy period (EP). EP begins with the first treatment regimen dose of rFIXFc and ends with the last dose (regardless of the reason for dosing). Surgery/rehabilitation periods are not included in the EP. Participants were included in summary of more than 1 treatment regimen if their regimen changed during study.
Time Frame Up to 3 years
Hide Outcome Measure Data
Hide Analysis Population Description
Analysis performed on FAS. Here, number analyzed signifies number of bleeding episodes reported for each treatment regimen.
Arm/Group Title Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc)
Hide Arm/Group Description:
Participants received rFIXFc IV injection as follows: Prophylactic treatment regimen: started with rFIXFc 50 IU/kg weekly until a participant reached at least 50 exposure days (ED=24-hour period in which >=1 injection/dose of rFIXFc was given) to rFIXFc, withdrawal from study or end of study. Adjustments to dose and dosing interval was based on incremental recovery, subsequent Factor IX levels, physical activity, bleeding pattern, in accordance with local standards of care for prophylactic regimen (PR). Treatment with episodic (on demand) regimen can be initiated before PR at investigators discretion. Episodic (On demand; optional): rFIXFc at individual doses based on participant's clinical condition, type and severity of bleeding event until PR.
Overall Number of Participants Analyzed 33
Overall Number of Units Analyzed
Type of Units Analyzed: Bleeding episodes
85
Median (Full Range)
Unit of Measure: IU/kg
Episodic regimen Number Analyzed 27 Bleeding episodes [1] 
88.50
(41.7 to 178.6)
Prophylaxis regimen Number Analyzed 58 Bleeding episodes [2] 
71.92
(23.3 to 181.8)
[1]
22 participants
[2]
28 participants
9.Secondary Outcome
Title Change From Baseline in rFIXFc Incremental Recovery (IR)
Hide Description Blood samples were taken at trough and Cmax (maximum concentration) for assessment of incremental recovery, measured by the one-stage clotting assay. IR (International Units per deciliter [IU/dL] per IU/kg) = (Cmax for FIX activity - Pre-dose FIX activity) (IU/dL)/ Actual dose (IU/kg), where Cmax is 30 minute FIX activity post-dose and FIX activity less than (<)0.5 IU/dL was set to 0 IU/dL for calculation of IR.
Time Frame Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, and 144
Hide Outcome Measure Data
Hide Analysis Population Description
Analysis performed on FAS. Here number analyzed signifies number of FAS participants with available data for each visit.
Arm/Group Title Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc)
Hide Arm/Group Description:
Participants received rFIXFc IV injection as follows: Prophylactic treatment regimen: started with rFIXFc 50 IU/kg weekly until a participant reached at least 50 exposure days (ED=24-hour period in which >=1 injection/dose of rFIXFc was given) to rFIXFc, withdrawal from study or end of study. Adjustments to dose and dosing interval was based on incremental recovery, subsequent Factor IX levels, physical activity, bleeding pattern, in accordance with local standards of care for prophylactic regimen (PR). Treatment with episodic (on demand) regimen can be initiated before PR at investigators discretion. Episodic (On demand; optional): rFIXFc at individual doses based on participant's clinical condition, type and severity of bleeding event until PR.
Overall Number of Participants Analyzed 33
Median (Inter-Quartile Range)
Unit of Measure: IU/dL per IU/kg
Change at Week 12 Number Analyzed 14 participants
0.0
(-0.08 to 0.12)
Change at Week 24 Number Analyzed 15 participants
0.0
(-0.17 to 0.15)
Change at Week 36 Number Analyzed 18 participants
-0.0
(-0.18 to 0.11)
Change at Week 48 Number Analyzed 20 participants
-0.0
(-0.13 to 0.03)
Change at Week 60 Number Analyzed 17 participants
-0.1
(-0.1 to 0.03)
Change at Week 72 Number Analyzed 12 participants
-0.1
(-0.20 to 0.07)
Change at Week 84 Number Analyzed 10 participants
-0.1
(-0.23 to -0.04)
Change at Week 96 Number Analyzed 7 participants
-0.1
(-0.14 to 0.03)
Change at Week 108 Number Analyzed 4 participants
-0.1
(-0.36 to -0.01)
Change at Week 120 Number Analyzed 1 participants
-0.1
(-0.1 to -0.1)
Change at Week 132 Number Analyzed 1 participants
-0.1
(-0.1 to -0.1)
Change at Week 144 Number Analyzed 1 participants
0.0
(0.0 to 0.0)
Time Frame All Adverse Events (AEs) were collected from signature of the informed consent form up to end of the study (up to 3 years) regardless of seriousness or relationship to investigational product.
Adverse Event Reporting Description Reported AE are treatment-emergent AE i.e. AE that was present prior to receiving first injection of rFIXFc and subsequently worsened in severity, or was not present prior to receiving first injection but subsequently appeared before last visit/follow-up call, whichever came later. Analysis performed on safety analysis set.
 
Arm/Group Title Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc)
Hide Arm/Group Description Participants received rFIXFc IV injection as follows: Prophylactic treatment regimen: started with rFIXFc 50 IU/kg weekly until a participant reached at least 50 exposure days (ED=24-hour period in which >=1 injection/dose of rFIXFc was given) to rFIXFc, withdrawal from study or end of study. Adjustments to dose and dosing interval was based on incremental recovery, subsequent Factor IX levels, physical activity, bleeding pattern, in accordance with local standards of care for prophylactic regimen (PR). Treatment with episodic (on demand) regimen can be initiated before PR at investigators discretion. Episodic (On demand; optional): rFIXFc at individual doses based on participant's clinical condition, type and severity of bleeding event until PR.
All-Cause Mortality
Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc)
Affected / at Risk (%)
Total   0/33 (0.00%)    
Hide Serious Adverse Events
Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc)
Affected / at Risk (%) # Events
Total   23/33 (69.70%)    
Blood and lymphatic system disorders   
Anaemia  1  1/33 (3.03%)  1
Factor ix inhibition  1  1/33 (3.03%)  1
Immune thrombocytopenic purpura  1  1/33 (3.03%)  1
Congenital, familial and genetic disorders   
Phimosis  1  1/33 (3.03%)  1
Gastrointestinal disorders   
Inguinal hernia  1  1/33 (3.03%)  1
Tongue haemorrhage  1  1/33 (3.03%)  1
General disorders   
Vessel puncture site haematoma  1  1/33 (3.03%)  1
Immune system disorders   
Hypersensitivity  1  1/33 (3.03%)  1
Infections and infestations   
Croup infectious  1  1/33 (3.03%)  1
Gastroenteritis  1  1/33 (3.03%)  1
Infusion site pustule  1  1/33 (3.03%)  1
Lower respiratory tract infection  1  1/33 (3.03%)  1
Respiratory tract infection  1  1/33 (3.03%)  1
Staphylococcal bacteraemia  1  1/33 (3.03%)  1
Viral infection  1  1/33 (3.03%)  1
Viral rash  1  1/33 (3.03%)  1
Injury, poisoning and procedural complications   
Accidental exposure to product  1  1/33 (3.03%)  1
Craniocerebral injury  1  1/33 (3.03%)  1
Face injury  1  1/33 (3.03%)  1
Fall  1  5/33 (15.15%)  9
Head injury  1  3/33 (9.09%)  8
Skull fracture  1  1/33 (3.03%)  1
Subdural haematoma  1  1/33 (3.03%)  1
Musculoskeletal and connective tissue disorders   
Compartment syndrome  1  1/33 (3.03%)  1
Haemarthrosis  1  1/33 (3.03%)  1
Nervous system disorders   
Coma  1  1/33 (3.03%)  1
Febrile convulsion  1  1/33 (3.03%)  1
Spinal cord haematoma  1  1/33 (3.03%)  1
Tongue biting  1  1/33 (3.03%)  1
Reproductive system and breast disorders   
Prepuce redundant  1  1/33 (3.03%)  1
Surgical and medical procedures   
Central venous catheterisation  1  9/33 (27.27%)  9
Vascular disorders   
Haematoma  1  1/33 (3.03%)  1
Poor venous access  1  3/33 (9.09%)  3
1
Term from vocabulary, MedDra 22.0
Indicates events were collected by systematic assessment
Hide Other (Not Including Serious) Adverse Events
Frequency Threshold for Reporting Other Adverse Events 5%
Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc)
Affected / at Risk (%) # Events
Total   27/33 (81.82%)    
Ear and labyrinth disorders   
Middle ear effusion  1  2/33 (6.06%)  2
Gastrointestinal disorders   
Constipation  1  2/33 (6.06%)  3
Diarrhoea  1  5/33 (15.15%)  9
Teething  1  6/33 (18.18%)  15
Vomiting  1  4/33 (12.12%)  8
General disorders   
Pyrexia  1  14/33 (42.42%)  33
Infections and infestations   
Bronchitis  1  2/33 (6.06%)  4
Conjunctivitis  1  2/33 (6.06%)  2
Croup infectious  1  2/33 (6.06%)  2
Ear infection  1  4/33 (12.12%)  4
Hand-foot-and-mouth disease  1  2/33 (6.06%)  2
Influenza  1  3/33 (9.09%)  3
Nasopharyngitis  1  11/33 (33.33%)  22
Otitis media  1  4/33 (12.12%)  8
Pharyngitis  1  4/33 (12.12%)  5
Rhinitis  1  3/33 (9.09%)  5
Upper respiratory tract infection  1  7/33 (21.21%)  12
Varicella  1  4/33 (12.12%)  4
Viral infection  1  4/33 (12.12%)  6
Viral rash  1  3/33 (9.09%)  3
Viral upper respiratory tract infection  1  2/33 (6.06%)  3
Injury, poisoning and procedural complications   
Contusion  1  2/33 (6.06%)  2
Fall  1  7/33 (21.21%)  13
Head injury  1  5/33 (15.15%)  7
Investigations   
Blood alkaline phosphatase increased  1  3/33 (9.09%)  3
White blood cell count increased  1  2/33 (6.06%)  2
Metabolism and nutrition disorders   
Iron deficiency  1  3/33 (9.09%)  4
Psychiatric disorders   
Irritability  1  2/33 (6.06%)  2
Reproductive system and breast disorders   
Balanoposthitis  1  2/33 (6.06%)  2
Respiratory, thoracic and mediastinal disorders   
Asthma  1  2/33 (6.06%)  3
Cough  1  6/33 (18.18%)  11
Nasal congestion  1  2/33 (6.06%)  2
Oropharyngeal pain  1  3/33 (9.09%)  3
Rhinorrhoea  1  6/33 (18.18%)  18
Skin and subcutaneous tissue disorders   
Dermatitis diaper  1  4/33 (12.12%)  5
Dry skin  1  2/33 (6.06%)  2
Eczema  1  3/33 (9.09%)  4
Erythema  1  2/33 (6.06%)  2
Rash  1  3/33 (9.09%)  4
1
Term from vocabulary, MedDra 22.0
Indicates events were collected by systematic assessment
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.
Results Point of Contact
Layout table for Results Point of Contact information
Name/Title: Trial Transparency Team
Organization: Bioverativ, a Sanofi company
Phone: 800-633-1610 ext 6
EMail: Contact-US@sanofi.com
Layout table for additonal information
Responsible Party: Sanofi ( Bioverativ, a Sanofi company )
ClinicalTrials.gov Identifier: NCT02234310    
Other Study ID Numbers: 998HB303
2013-003629-27 ( EudraCT Number )
First Submitted: July 17, 2014
First Posted: September 9, 2014
Results First Submitted: July 15, 2020
Results First Posted: July 31, 2020
Last Update Posted: July 31, 2020